Circulating tumor DNA (ctDNA) molecular residual disease (MRD)
Circulating tumor DNA (ctDNA) molecular residual disease (MRD) is a biomarker used in companion diagnostic testing.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where Circulating tumor DNA (ctDNA) molecular residual disease (MRD) is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Muscle Invasive Bladder Cancer (MIBC) Solid Tumor |
|
Approvals defined at the solid tumor level where Circulating tumor DNA (ctDNA) molecular residual disease (MRD) is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report Circulating tumor DNA (ctDNA) molecular residual disease (MRD) as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports Circulating tumor DNA (ctDNA) molecular residual disease (MRD) as part of its biomarker panel.